EIS 12656
Alternative Names: EIS-12656Latest Information Update: 23 May 2024
At a glance
- Originator Eisbach Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action CHD1L protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 May 2024 Eisbach Bio plans a phase I/II trial for Solid tumours (Monotherapy, Late-stage disease) in the US the second quarter of 2024
- 06 May 2024 US FDA approves IND application for EIS 12656 in Solid tumour
- 21 Mar 2024 Preclinical trials in Cancer in Germany (unspecified route) before March 2024